These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 34348844)

  • 1. Insurance reimbursements for recombinant zoster vaccine in the private sector.
    Leidner AJ; Tang Z; Guo A; Anderson TC; Tsai Y
    Vaccine; 2021 Aug; 39(36):5091-5094. PubMed ID: 34348844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insurance Reimbursements for Routinely Recommended Adult Vaccines in the Private Sector.
    Tsai Y; Zhou F; Lindley MC
    Am J Prev Med; 2019 Aug; 57(2):180-190. PubMed ID: 31248743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
    Parikh R; Widenmaier R; Lecrenier N
    Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of use of recombinant zoster vaccine among commercially-insured immunocompetent and immunocompromised adults 50-64 years old in the United States.
    Fix J; Vielot NA; Lund JL; Weber DJ; Smith JS; Hudgens MG; Becker-Dreps S
    Vaccine; 2023 Jan; 41(1):49-60. PubMed ID: 36396511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
    Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
    MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults.
    Janusz CB; Anderson TC; Leidner AJ; Lee GM; Dooling K; Prosser LA
    Hum Vaccin Immunother; 2022 Nov; 18(5):2060668. PubMed ID: 35476029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries.
    Goud R; Lufkin B; Duffy J; Whitaker B; Wong HL; Liao J; Lo AC; Parulekar S; Agger P; Anderson SA; Wernecke M; MaCurdy TE; Weintraub E; Kelman JA; Forshee RA
    JAMA Intern Med; 2021 Dec; 181(12):1623-1630. PubMed ID: 34724025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
    Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
    MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant zoster vaccine (RZV) second-dose series completion in adults aged 50-64 years in the United States.
    Leung J; Gray EB; Anderson TC; Sharkey SM; Dooling K
    Vaccine; 2022 Nov; 40(50):7187-7190. PubMed ID: 36347721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant zoster vaccine coverage in the United States: An analysis of claims-based data.
    Lewis CY; Mishra K; Sun Y; Sechrist SJ; Arnold BF; Acharya NR
    Vaccine; 2023 May; 41(23):3493-3496. PubMed ID: 37150621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults With Immune-Mediated Inflammatory Diseases in the US.
    Leung J; Anderson TC; Dooling K; Xie F; Curtis JR
    Arthritis Rheumatol; 2022 Nov; 74(11):1833-1841. PubMed ID: 35666070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Attitudes, barriers, and facilitators to adherent completion of the recombinant zoster vaccine regimen in Canada: Qualitative interviews with healthcare providers and patients.
    George S; Regan J; Awan A; O'Connor M; Foster A; Raymond K; Gorfinkel I; McNeil SA
    Hum Vaccin Immunother; 2024 Dec; 20(1):2317595. PubMed ID: 38502342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.
    Pirrotta P; Tavares-Da-Silva F; Co M; Lecrenier N; Hervé C; Stegmann JU
    Drug Saf; 2021 Dec; 44(12):1341-1353. PubMed ID: 34622421
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of the Recombinant Zoster Vaccine for Herpes Zoster Ophthalmicus in the United States.
    Lu A; Sun Y; Porco TC; Arnold BF; Acharya NR
    Ophthalmology; 2021 Dec; 128(12):1699-1707. PubMed ID: 33892049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
    Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
    Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early examination of real-world uptake and second-dose completion of recombinant zoster vaccine in the United States from October 2017 to September 2019.
    Patterson BJ; Chen CC; McGuiness CB; Glasser LI; Sun K; Buck PO
    Hum Vaccin Immunother; 2021 Aug; 17(8):2482-2487. PubMed ID: 33849373
    [No Abstract]   [Full Text] [Related]  

  • 19. Real-world evidence on adherence and completion of the two-dose recombinant zoster vaccine and associated factors in U.S. adults, 2017-2021.
    LaMori J; Feng X; Pericone CD; Mesa-Frias M; Sogbetun O; Kulczycki A
    Vaccine; 2022 Apr; 40(15):2266-2273. PubMed ID: 35292160
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term efficacy data for the recombinant zoster vaccine: impact on public health and cost effectiveness in Germany.
    Curran D; Van Oorschot D; Matthews S; Hain J; Salem AE; Schwarz M
    Hum Vaccin Immunother; 2021 Dec; 17(12):5296-5303. PubMed ID: 34905463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.